About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Impact of Covid-19 in Congenital Heart Disease

NCT04336384·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Montpellier

With

Pr. Jean-Benoît THAMBO, Bordeaux (président)
Dr. Céline GRUNENWALD GRONIER, Strasbourg
Dr. Sébastien HASCOET, Le Plessis-Robinson
Dr. Adeline BASQUIN, Rennes
Dr. Nicolas COMBES, Toulouse
Dr. Xavier IRIART, Bordeaux
Dr. Daniela LAUX, Paris
Dr. Magalie LADOUCEUR, Paris
Pr. BERTRAND LEOBON, Toulouse
Pr. Caroline OVAERT, Marseille
Dr. Karine WARIN-FRESSE, Nantes
Alexis BLANC, Montpellier
Pr. Roland HENAINE, Lyon
Hamouda ABASSI, Montpellier

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patient with CHD as defined in the international classification ACC-CHD
Covid-19 infection over the study period

You may not be if

\- Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).

The record

StatusCompleted

PhaseNo phase

Taking part5,000

StartedMar 2020

UpdatedFeb 2, 2021

Conditions

Congenital Heart Disease Covid-19

Where1

Uh Montpellier
Montpellier, France

Clareo Health | Impact of Covid-19 in Congenital Heart Disease